TY - JOUR
T1 - Older patients with early-stage diffuse large B-cell lymphoma
T2 - the role of consolidation radiotherapy after chemoimmunotherapy
AU - Parikh, Rahul R.
AU - Yahalom, Joachim
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/3/4
Y1 - 2017/3/4
N2 - The purpose of this study was to examine the association between RT and overall survival for older patients (>60 years) with early-stage diffuse large B-cell lymphoma (DLBCL) using standard and propensity score (PS)-adjusted Cox proportional hazards models. From 1998 to 2012, 2207 patients were over the age of 60 years, received chemoimmunotherapy with or without RT and were included in this study. Use of consolidation RT was associated with lower clinical stage, head/neck involved site, lack of ‘B’ symptoms, lower co-morbidity score, and higher socioeconomic status (all p <.05). Examining 1721 patients for survival outcomes (1998–2008), the 5-year overall survival for patients receiving RT was 80.1% versus 69.8% for those not receiving RT (p <.01). After PS-matching for co-variates, RT use remained associated with improved overall survival (HR = 0.63, 95% CI, 0.51–0.79, p <.01). Over the study period, RT utilization decreased from 38.5% to 28.8%. Consolidation RT was associated with improved OS for older patients with early-stage DLBCL receiving chemoimmunotherapy.
AB - The purpose of this study was to examine the association between RT and overall survival for older patients (>60 years) with early-stage diffuse large B-cell lymphoma (DLBCL) using standard and propensity score (PS)-adjusted Cox proportional hazards models. From 1998 to 2012, 2207 patients were over the age of 60 years, received chemoimmunotherapy with or without RT and were included in this study. Use of consolidation RT was associated with lower clinical stage, head/neck involved site, lack of ‘B’ symptoms, lower co-morbidity score, and higher socioeconomic status (all p <.05). Examining 1721 patients for survival outcomes (1998–2008), the 5-year overall survival for patients receiving RT was 80.1% versus 69.8% for those not receiving RT (p <.01). After PS-matching for co-variates, RT use remained associated with improved overall survival (HR = 0.63, 95% CI, 0.51–0.79, p <.01). Over the study period, RT utilization decreased from 38.5% to 28.8%. Consolidation RT was associated with improved OS for older patients with early-stage DLBCL receiving chemoimmunotherapy.
KW - National Cancer Database
KW - Non-Hodgkin lymphoma
KW - consolidation radiotherapy
KW - elderly
KW - overall survival
UR - https://www.scopus.com/pages/publications/84981170006
U2 - 10.1080/10428194.2016.1205739
DO - 10.1080/10428194.2016.1205739
M3 - Article
C2 - 27685446
AN - SCOPUS:84981170006
SN - 1042-8194
VL - 58
SP - 614
EP - 622
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -